Department of Neurosurgery, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
J Neurotrauma. 2010 Sep;27(9):1723-32. doi: 10.1089/neu.2010.1276.
The effects of R-type calcium channels on cerebral blood flow (CBF) and vasospasm pathways following subarachnoid hemorrhage (SAH) have not been well studied. The aim of this study was to investigate the role of R-type calcium channels in vasospasm development and treatment. Sixty-five rats were randomly divided into four groups: sham (n = 14), SAH (n = 17), SAH + nimodipine (n = 17), and SAH + SNX-482 (n = 17). A prechiasmatic SAH model was constructed on day 0. Then 5 μg of nimodipine (an L-type calcium channel antagonist) or 0.1 μg of SNX-482 (an R-type calcium channel antagonist) was infused intracisternally on days 1 and 2. On day 3, neurological status was evaluated and CBF was determined using fluorescent microspheres. The extent of myosin light chain-2 (MLC2) phosphorylation was determined by urea-glycerol polyacrylamide gel electrophoresis, followed by immunoblotting. The relative presence of R-type calcium channels and calponin was determined by SDS polyacrylamide gel electrophoresis, followed by immunoblotting. Numbers of R-type calcium channels increased following SAH, and neurological deficit, CBF reduction, and enhancement of MLC2 phosphorylation as well as calponin degradation were all found to be present. There were no statistically significant differences in neurological scores among the SAH, SAH + nimodipine, and SAH + SNX-482 groups. Nimodipine had no significant effect on CBF reduction compared to the SAH group (p > 0.008), whereas SNX-482 significantly inhibited CBF reduction (p < 0.008). Both MLC2 phosphorylation and calponin degradation appeared to be inhibited by SNX-482, whereas the effects of nimodipine were relatively blunted. We concluded that an R-type calcium channel antagonist may improve CBF following SAH by partially inhibiting MLC2 phosphorylation and calponin degradation, and may exceed the potential of an L-type calcium channel antagonist, which suggests a more crucial role for R-type calcium channels in the development of SAH vasospasm and its treatment.
R 型钙通道对蛛网膜下腔出血(SAH)后脑血流(CBF)和血管痉挛途径的影响尚未得到很好的研究。本研究旨在探讨 R 型钙通道在血管痉挛发展和治疗中的作用。65 只大鼠随机分为四组:假手术组(n=14)、SAH 组(n=17)、SAH+尼莫地平组(n=17)和 SAH+SNX-482 组(n=17)。于第 0 天构建前交通支蛛网膜下腔出血模型。然后于第 1 天和第 2 天分别鞘内注入 5μg 尼莫地平(L 型钙通道拮抗剂)或 0.1μg SNX-482(R 型钙通道拮抗剂)。第 3 天,通过荧光微球评估神经状态并测定 CBF。通过尿素-甘油聚丙烯酰胺凝胶电泳测定肌球蛋白轻链-2(MLC2)磷酸化程度,然后进行免疫印迹。通过 SDS 聚丙烯酰胺凝胶电泳,然后进行免疫印迹,确定 R 型钙通道和钙调蛋白的相对存在。SAH 后 R 型钙通道数量增加,发现神经功能缺损、CBF 减少以及 MLC2 磷酸化和钙调蛋白降解增强。SAH、SAH+尼莫地平组和 SAH+SNX-482 组之间的神经评分无统计学差异。与 SAH 组相比,尼莫地平对 CBF 减少无显著影响(p>0.008),而 SNX-482 则显著抑制 CBF 减少(p<0.008)。SNX-482 似乎抑制了 MLC2 磷酸化和钙调蛋白降解,而尼莫地平的作用相对较弱。我们得出结论,R 型钙通道拮抗剂可能通过部分抑制 MLC2 磷酸化和钙调蛋白降解来改善 SAH 后的 CBF,并且可能超过 L 型钙通道拮抗剂的作用,这表明 R 型钙通道在 SAH 血管痉挛的发展及其治疗中发挥更重要的作用。